National Advisory Council (NANDSC) Meeting - May 2020

Contact: Kelly Baker
Contact Number: 301-496-9248
Contact Email: kelly.baker@nih.gov
Location:

Remote Meeting/Webcast Only.
Open Session on May 27th can be viewed at: https://videocast.nih.gov/watch=36177

---

The 208^th meeting of the National Advisory Neurological Disorders and Stroke Council will be held on Wednesday, May 27 - Thursday, May 28, 2020. For more information, visit the Advisory Council web page.

Related Resources

Agenda

May 27, 2020

Open Session

May 28, 2020

Closed Session

Meeting Minutes

Summary of Meeting¹
 

The National Advisory Neurological Disorders and Stroke (NANDS) Council was convened for its 208^th meeting on May 27-28, 2020 via WebEx remote meeting. Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke (NINDS), served as Chairperson.

In accordance with Public Law 92-463, the meeting was:

Open:       May 27, 2020: 1:00 p.m. to 6:12 p.m. for the review and discussion of program development, needs, and policy; and
Closed:    May 28, 2020: 1:00 p.m. to 5:20 p.m. for the consideration of individual grant applications.

Council members present:
Dr. Laurence Abbott
Dr. Issam Awad
Dr. Allan Basbaum
Dr. S. Thomas Carmichael
Dr. Hollis Cline
Ms. Susan Dickinson
Dr. Nita Farahany (telephone)
Dr. Aaron Gitler
Dr. David Hackney
Dr. Karen Johnston
Dr. Arnold Kriegstein
Dr. Claudia Lucchinetti
Dr. Kenneth Maynard
Ms. Eileen Murray
Dr. Indira Raman
Dr. Steven Roberds
Dr. N. Edwin Trevathan
Ms. Christin Veasley

Ex officio member present:
David Brody, M.D., Ph.D., Department of Defense
Christopher Bever, Jr., M.D., Department of Veterans Affairs

Members of the public present for portions of the open meeting included:
Amy Brooks-Kayal, University of Colorado, Children’s Hospital Colorado

Federal attendees are listed at the end of these minutes.

I.  Call to Order and Opening Remarks

Dr. Koroshetz welcomed Council members, visitors, and staff to the 208th meeting of the National Advisory Neurological Disorders and Stroke Council.

II.  Report of the Director, Division of Extramural Activities, NINDS

Approval of Council Minutes — Dr. Finkelstein requested, and the Council voted approval of the February 5-6, 2020, Council meeting minutes.

The following future Council meeting dates were confirmed:

Wednesday & Thursday, May 27-28, 2020
Wednesday & Thursday, September 9-10, 2020
Wednesday & Thursday, February 3-4, 2021 (updated)
Wednesday & Thursday, May 26-27, 2021
Wednesday & Thursday, September 8-9, 2021
Wednesday & Thursday February 2-3, 2022
Wednesday & Thursday, May 18-19, 2022
Wednesday & Thursday, September 7-8, 2022

Approval of Council Operation Procedures — Dr. Finkelstein requested, and the Council voted to approve the 2020 NINDS Advisory Council Operating Procedures with updates to the Delegation of Authority for a Federal emergency.

Expedited Review Process – Each Council round, a subset of Council members approves applications in advance of the meeting with scores within the payline. This expedited review process focuses on applications for which there are no unresolved issues. Dr. Finkelstein thanked Council members Indira Raman, Susan Dickinson, and Karen Johnston for handling this responsibility for this meeting and the fiscal year. For the current Council round, 190 applications were eligible to be expedited. A portion of these awards already have been issued, and the others will be issued after Council.

Extramural Announcements

Dr. John J. Ngai joined NIH in March as Director of the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative.

Dr. Koroshetz welcomed new Council member Dr. David L. Brody and acknowledged the important contributions made by outgoing Council members Drs. Laurence Abbott, Issam A. Awad, Indira M. Raman, and Steven L. Roberds.

III.  Report of the Director, NINDS

Dr. Walter Koroshetz, Director, NINDS

NIH News — Dr. Koroshetz announced that a NANDS Council Working Group will be formed to develop the NIH Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Research Roadmap and asked for volunteers to participate in this effort. ME/CFS researchers, clinicians, patient advocates, and researchers from other scientific areas will work in small groups assigned to specific ME/CFS topics. Public input will be incorporated into final Roadmap, which will be presented to NANDS Council.

Budget — NINDS has received budget increases from 2016 onward and was appropriated a disproportionately larger increase in Fiscal Year (FY) 2020. In addition, the Institute received $266 million for pain research as part of the Helping to End Addiction Long-term (HEAL) Initiative and $70 million from the 21st Century Cures Act for the BRAIN® Initiative. NINDS co-manages approximately $212.5 million of the Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) monies received by the National Institute on Aging (NIA).

COVID-19 — NIH and NINDS are deeply concerned for the health and safety of people involved in NIH research—employees, grantees, subjects enrolled in clinical trials—and about the impact of COVID-19 on the biomedical enterprise. In the past few months, a considerable amount of funding has come to NIH Institutes and the NIH Office of Director (OD) for COVID-19 research. For example, the National Institute of Environmental Health Sciences (NIEHS) received $10 million for worker-based training programs to prevent and reduce exposure of frontline workers to the virus, the National Institute of Allergy and Infectious Diseases (NIAID) received $706 million to develop antiviral agents, the National Institute of Biomedical Imaging and Bioengineering(NIBIB) received $500 million to accelerate rapid testing of devices for coronavirus and antibody detection, and the National Cancer Institute (NCI) received $306 million to develop, improve, validate, and implement serological testing for COVID-19 and associated technologies. To date, NINDS has not received any funds for COVID-19.

Dr. Koroshetz outlined provisions of House Bill 6800, The HEROES Act, that included additional funding for the NIH OD to “prevent, prepare, and respond to coronavirus.”
NIH, the Foundation for the NIH (FNIH), other federal agencies, and over a dozen leading biopharmaceutical companies have launched the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership. ACTIV will develop a collaborative framework to prioritize vaccine and drug candidates, streamline clinical trials, and coordinate regulatory processes for a rapid response to COVID-19 and future pandemics.

The NIH Rapid Acceleration of Diagnostics (RADx) initiative aims at speeding innovation, development, and commercialization of COVID-19 testing technologies. RADx will expand the NIBIB Point-of-Care Technologies Research Network (POCTRN) established several years ago.

To expedite COVID-19 funding to the research community, NIH is using Urgent and Emergency competing revisions and administrative supplements to existing grant awards. 

NIH is providing many administrative flexibilities to help research continue. These include allowing pre-award costs to be incurred, extensions of post-award reporting, prior approval requirement waivers, and numerous flexibilities regarding expenditures of funds. NIH accommodations for loss of research time include consideration of extensions for early-stage investigator eligibility due to COVID-19-related disruptions; flexibility for extending time constraints for fellowship, career development, and training awards, including phased awards; and extensions on specific application receipt dates.

Dr. Koroshetz described potential neurological effects of COVID-19. Although evidence that the virus can be found in the brain is thin, brain endothelial cells are known to express ACE2 by which the virus enters cells. Infection is associated with prothrombotic state, large artery stroke, and thrombosis in small blood vessels in the brain, heart, lungs, and other organs. The virus triggers a “cytokine storm” linked to a number of parainfectious neurological conditions.  Neurological complications of infection include potential for long-term cognitive disability and stroke. Following recovery from COVID-19 infection, rare cases of acute necrotizing hemorrhagic encephalopathy, transverse myelitis, Guillain Barre Syndrome, and Kawasaki syndrome have been reported.

NINDS has issued two Notices of Special Interest (NOSIs) related to Coronavirus: NOT-NS-20-051, Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System, and  NOT-NS-20-046, Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2.

Dr. Koroshetz outlined key concerns about the impact of COVID-19 on research. Trainees who are due to transition to their next career stage may not be able to matriculate due to hiring freezes.  Milestoned research projects will not achieve initial expectations and will require more time and funds. Researchers on work visas may need to return home and could be forced out of U.S. academia. A gender-related decrease in journal submissions is likely due to heavy care burdens in the home.

Restarting the neuroscience research enterprise (i.e., non-COVID clinical, translational, and basic research predominantly paused in March) is likely to take months and require additional resources. Challenges include rebuilding animal colonies and providing safe access to labs and core facilities. Recovering from clinical trial enrollment disruptions could take over a year. Most NINDS clinical trials are on pause; although medications can be mailed, other treatments and neurological exams must be done in person.

Despite a push for the adoption of modern technology in clinical trials, the industry has been slow to change. The pandemic has pushed researchers and industry to use telemedicine, virtual assessments, and digital informed consent to reduce in-person visits. These changes will increase efficiency and safety in the long term beyond the need created by the pandemic.

IV.  Discussion of Director’s Report

Council members discussed challenges and described action NINDS can take between now and the September Council meeting.

Challenges include the impact of the hiring freeze on trainees and others at key career transition points as well as on lab support; restricted ability to fund new innovative research if maintaining currently supported projects becomes the priority; the disconnect between return to work/full operation for working parents with children who otherwise would be in school; and exacerbation of workplace and economic disparities.

Recommended actions include looking at lessons learned from previous hiring freezes (e.g., 2008); offering special consideration to investigators who are bridged, those who would have been reapplying, and new investigators; providing guidance, standards, and validation for virtual study components; fully engaging in telemedicine-based neurological exams using the Department of Defense as a model; and establishing a Council working group to identify most vulnerable populations and possible solutions and put them forward to Council.

V.  Epilepsy Therapy Screening Program (ETSP) Report to Council

Dr. Amy Brooks-Kayal, Chair in Pediatric Neurology, Professor of Pediatrics, Neurology and Pharmaceutical Sciences, University of Colorado School of Medicine, Children’s Hospital Colorado

Dr. Brooks-Kayal presented a Working Group report on an evaluation of the ETSP. She outlined ETSP processes and its history. Currently, ETSP costs $4.57 million a year, with the major portion of funds going to the contract site and the remainder supporting the NINDS ETSP Director, Dr. Brian Klein, plus five NIH staff dedicated to supporting the Program. Dr. Brooks-Kayal described progress on implementation of responses and recommendations from the 2015 ETSP evaluation. These include establishing an external consultant board (ECB) to provide ongoing advice.

The 2020 ETSP Working Group priorities include enhancing early consideration of ADME issues in the screening process; prioritizing development and implementation of epileptogenesis and disease modification testing models for more rapid translation to humans; and encouraging testing of non-small-molecule therapies. The Group recommends that NINDS proactively explore and conduct outreach to identify drugs that have novel mechanisms and targets. Council noted the ETSP addresses the unmet needs of people with epilepsy, including drug refractory epilepsy, epileptogenesis, and disease modification.

Council voted to accept the Working Group report.

VI.  NINDS Strategic Plan

Dr. Nina Schor, Deputy Director, NINDS

Dr. Schor described the NINDS strategic planning process as a grassroots initiative, partnership, and bidirectional exchange between NINDS and numerous external advisors. She noted that the content and implementation plans prepared to date may require modification due to the increased need for innovation in the context of unanticipated obstacles created by COVID-19.

NINDS leadership framed the vision, mission, and strategic goals. The NINDS vision is “the discovery, innovation, research, and education performed and enabled by NINDS frees the world from the restriction and burden of neurological disorders.” The NINDS mission is “to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.” Overarching goals include being a model of excellence for supporting and performing significant, innovative, and rigorous neuroscience research; being a model of excellence for funding and conducting neuroscience research training and career development programs and ensuring a vibrant, talented, and diverse neuroscience workforce; promoting dynamic communication and stakeholder engagement to accelerate scientific progress and reduce the burden of neurological disorders; and creating and sustaining a supportive work culture for the NINDS workforce that becomes the model for biomedical research and the neuroscience community.

Responses to the Request for Information (RFI) identified common themes: collaboration, grants and funding, scientific rigor, data science, and patient inclusion and quality of life. The Steering Committee charged taskforces (i.e., science; training and diversity; communication; and workforce and workplace culture) with drafting operational objectives to inform a roadmap for achieving the NINDS vision in the next five years.

Council members discussed how the objectives might address the disruption caused by COVID-19, how to inform the public about what can be learned from studying the normal nervous system and incorporating entrepreneurship in the objectives.

VII. Discussion of the R35 Checkpoint Policy

Dr. Anna Taylor, Program Director, Division of Extramural Activities, NINDS

Dr. Taylor provided background information about the R35 Checkpoint Policy. The goal of the Policy is to create a stable and flexible funding vehicle for outstanding NINDS investigators, facilitate longer-term and/or higher-risk research, reduce pressure to generate results quickly to renew short-term grants, provide flexibility to follow up on serendipitous research findings and/or explore new research directions, and reduce time spent writing applications and administering multiple grants.

Council members commented on outreach to encourage applications from diverse groups and perspectives, balancing awardees across career stage, and whether the R35 should be renewable.

VIII. Initiatives Requiring Concept Clearance

1. Platform Trials of Thrombectomy in Acute Stroke Treatment
   Dr. Clinton Wright, Director, Division of Clinical Research
   
   The proposed NOSI would employ master protocols to examine multiple important clinical questions (not prioritized by industry) that take a long view on patient benefits and public health impact, obtain answers in timely and efficient ways leveraging existing infrastructure (e.g., StrokeNet), and employ innovative clinical trial designs.
    
2. Accelerating Leading-edge Science for ALS (ALS2)
   Amelie Gubitz, Program Director, Division of Neuroscience
   
   The proposed Amyotrophic Lateral Sclerosis (ALS) initiative aims to explore entirely new research directions or bring powerful new tools to investigate the complex basic biology of ALS. The initiative is structured as a companion to the NIH Director’s Transformative Research Award (tR01) NIH’s Common Fund High-Risk, High-Reward Research program. It will be conducted in partnership with the NIA, NIEHS, and NIGMS.  The program supports individuals or teams proposing transformative projects that are inherently risky and untested but have the potential to create or overturn fundamental paradigms:  it is open to all career stages and no preliminary data is required. Interdisciplinary research projects and collaborations between ALS experts and scientists in cell biology, biophysics will be encouraged.
3. Proposal to Expand NIH Blueprint for Neuroscience Research (BPN) to Include Biotherapeutics
   Dr. Chris Boshoff, Program Director, Division of Translational Research
   
   Building on BPN’s current success with small molecules, the proposal aims to support academic and small business biotherapeutics projects to encourage industry investment in new therapies for patients with nervous system disorders. Expected outcomes include delivery of one to two biotherapeutics to clinical trials by the end of five years, create synergy with existing BPN resources, and provide infrastructure and expertise not currently available for biotherapeutics.

Council voted to approve the above proposed initiatives.

4. Blueprint MedTech
   Nick Langhals, Program Director, Division of Translational Research
   
   The proposed program aims to solve challenges for new diagnostic and therapeutic technologies along the development pipeline that stall due to lack of expertise and resources required for translation. The program will combine the strengths of academia, industry, and government to de-risk groundbreaking devices that may otherwise stall at early steps towards translation. It would also match technology developers with commercialization and disease experts, and provide resources to support the entire ecosystem around technology translation.
5. NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    Dr. Claudia Moy, Program Director, Division of Clinical Research
   
   The goal of this program is to provide a mechanism for the submission of applications for clinical trial, biomarker validation studies, and ancillary studies to be conducted within StrokeNet. The proposal for the reissue of this FOA is to shift the current FOA to a phased cooperative agreement mechanism that provides a formal one-year milestone-driven startup phase (UG3) to ensure that the study is on target and, if so, fund an additional six years for implementation (UH3).
6. NINDS Exploratory Grant Program in Parkinson’s Disease Research (P20 Clinical Trial Optional) and Morris K. Udall Centers of Excellence for Parkinson’s Disease Research (P50 Clinical Trial Optional)
    Dr. Beth-Anne Sieber, Program Director, Division of Neuroscience
   
   The Udall Centers Support innovative, rigorous research programs and collaborations to accelerate understanding of key questions in PD. They serve as local and national resources for PD research. The current proposal includes renewal of the congressionally mandated Udall Centers (P50) and funding for an exploratory grant program (P20) to formalize collaborative structures and establish a foundation of research discovery that would lead to a subsequent competitive application for a Udall Center P50.
   
   Council voted to approve the above proposed initiatives.
7. Reissue: The NINDS Human Biospecimen and Data Repository (U24)
   Dr. Christine Swanson-Fischer/Dr. Daniel Miller, Program Directors, Division of Extramural Activities
   
   This widely used repository houses 300,000 sample aliquots from 5,000 individuals, most of whom have various neurodegenerative disorders.  This is a successful initiative that is being reissued.
8. Sound Health: Understanding the Healing Power of Music
   Dr. Bob Riddle, Program Director, Division of Neuroscience
   
   The proposed initiative is a collaboration between the NIH OD and multiple NIH Institutes. This is a scaled-down version of prior initiatives supported by set-asides. This version will have a study section, but there are no set-aside funds.
9. Reissue: Research Program Award (R35)
   Dr. Anna Taylor, Program Director, Division of Extramural Activities
   
   The proposal is to reissue a Request for Applications (RFA) for a one-year iteration of the R35 awards that Dr. Taylor described earlier in the Council meeting.

Alzheimer’s Disease and Related Dementias
Dr. Finkelstein noted that the following seven initiatives are primarily renewals of existing RFAs that draw from funds allocated for ADRDs.

10. Small Vessel VCID Biomarker Consortium Project Sites
    Dr. Rod Corriveau, Program Director, Division of Neuroscience
11. Small Vessel VCID Biomarker Validation Consortium Coordinating Center (U24)
    Dr. Rod Corriveau, Program Director, Division of Neuroscience
12. Center without Walls for Molecular Mechanisms of Neurodegeneration in Frontotemporal Degeneration (FTD) (U54 Clinical Trial not Allowed)
    Drs. Amelie Gubitz and Rod Corriveau, Program Directors, Division of Neuroscience
13. Mechanisms of Selective Vulnerability in LBD and FTD
    Drs. Debra Babcock and Rod Corriveau, Program Directors, Division of Neuroscience
14. Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD
    Drs. Debra Babcock and Rod Corriveau, Program Directors, Division of Neuroscience
15. Connecting Pre-Mortem Clinical Information with Post-Mortem Brain Analysis
    Drs. Debra Babcock and Rod Corriveau, Program Directors, Division of Neuroscience
16. Treatments for Lewy Body Dementias—Exploratory Clinical Trial
    Drs. Debra Babcock and Rod Corriveau, Program Directors, Division of Neuroscience

Office of Programs to Enhance Neuroscience Workforce Diversity

17. Reissue: NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22)
    Dr. Michelle Jones-London, Chief, Office of Programs to Enhance Neuroscience Workforce Diversity
18. Reissue: NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01)
    Dr. Michelle Jones-London, Chief, Office of Programs to Enhance Neuroscience Workforce Diversity

Office of Training and Workforce Development

19. Reissue: NINDS Research Education Programs for Residents and Fellows and Administrative Supplements for Residents and Fellows
    Dr. Steve Korn, Director, Office of Training & Workforce Development

Council voted to approve the above proposed initiatives.

IX.  Council Consideration of Pending Applications

This portion of the meeting, involving specific grant review, was closed to the public.  The Council gave special attention to applications from foreign institutions and other applications requiring specific discussion.  Prior to discussion of the grants, Dr. Finkelstein reminded Council members regarding conflict of interest and confidentiality.

Conflict of Interest—Regulations concerning conflict of interest were reviewed.  Council members were reminded that materials furnished for review purposes and discussion during the closed portions of the meeting are considered privileged information. All Council members present signed a statement certifying that they had not been involved in any conflict-of-interest situations during the review of grant applications. 

Confidentiality—During the closed session, any information that is discussed and the outcome of any recommendation are considered privileged information.  They may not be discussed outside of the closed session.  If an applicant requests support for his or her application from a Council member, the Council member must respond that he/she is not permitted to discuss the application.  Any inquiry should be referred to Dr. Robert Finkelstein, NINDS Advisory Council Executive Secretary, who then will refer the question to the appropriate staff member for response. 

Research Training and Career Development Programs – The Council reviewed a total of 374 research career development and institutional training grant applications with primary assignment to NINDS, and 220 of them (59 percent) were scored in the amount of $19.8 million first-year direct costs.  It is anticipated that, of the research career development and institutional training grant applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $9.3 million (96 grants).

Research Project and Center Awards – The Council reviewed a total of 1,542 research project and center applications with primary assignment to NINDS, and 866 of them (56 percent) were scored/percentiled in the amount of $319.8 million first-year direct costs.  It is anticipated that, of the research grants competing at this Council, NINDS will be able to pay first-year direct costs of approximately $77.8 million (287 grants).

Senator Jacob Javits Neuroscience Investigator Awards – The Senator Jacob Javits Neuroscience Investigator Awards are made to distinguished investigators who have a record of scientific excellence and productivity, who are actively pursuing an area of research of strategic importance, and who can be expected to continue to be highly productive for a seven-year period.  Candidates are nominated and selected at each Council meeting.  Council approved four Javits nominations at this meeting: Robert W. Burgess, Ph.D. (The Jackson Laboratory), Aaron DiAntonio, M.D., Ph.D. (Washington University), Kimberly Huber, Ph.D. (UT Southwestern Medical Center), and Dalton James Surmeier, Ph.D. (Northwestern University).

Small Business Innovation Research and Small Business Technology Transfer Award Programs – The Council reviewed a total of 133 Small Business Innovation Research (SBIR) and Small Technology Transfer Award (STTR) grant applications with primary assignment to NINDS, and 68 of them (51 percent) were scored in the amount of $34.8 million first-year direct costs.  It is anticipated that, of the SBIR and STTR applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $11.7 million (20 grants).

X.  Adjournment

The meeting was adjourned at 5:20 p.m. on Thursday, May 28, 2020.

NINDS employees present for portions of the meeting included:

Amy Adams
DeAnna Adkins
Diana Andriola
Kari Ashmont
Debra Babcock
Shaunna Bach
Julia Bachman
Kelly Baker
Linda Bambrick
Rahul Banerjee
Karen Barnes
Jennifer Beierlein
Patrick Bellgowan
Alister Bennett
Karrah Benson
Richard Benson
Bill Benzing
Rebecca Berman
Francesca Bosetti
Chris Boshoff
Andrew Breeden
Ann-Marie Broome
Jeremy Brown
Ryan Calabrese
Roger Campbell
Emily Caporello
Stacey Chambers
Chi Chang
Maria Charlier
Denise Chatman
Thomas Cheever
Daofen Chen
Bo-Shiun Chen
Ben Churn
Liz Conklin
Robin Conwit
Janice Cordell
Roderick Corriveau
Devon Crawford
Diana Cummings
Charles Cywin
William Daley
Karen David
Sara Dauber
Sara Dodson
Jianxun Dong
Kristin Dupre
Debbie Eng
Judy Fabrikant
Christina Fang
Carlos Faraco
Robert Finkelstein
Nhi Floyd
Jane Fountain
Megan Frankowski
Alissa Gallagher
Shannon Garnett
Marie Gill
Paul Girolami
Jim Gnadt
Maureen Gormley
Terri Grasso
Brooks Gross
Amelie Gubitz
Mike Gyorda
Mohamed Hachicha
Maureen Hambrecht
Danielle Haney
Adam Hartman
Brandon Hartsell
Rebecca Hommer
Mir Ahamed Hossain
Nina Hsu
Eric Hudak
Xan Humphries
Smriti Iyengar
Lyn Jakeman
Scott Janis
Sophia Jeon
Dave Jett
Li Jia
Lisa Joliet
Michelle Jones-London
John Kehne
Brenda Kibler
Jenny Kim
Brian Klein
Jim Koenig
Stephen Korn
Walter Koroshetz
Sahana Kukke
Joseph Kurdziel
Pascal Laeng
Christine Lam
Cristina Saugar Lanchas
Nick Langhals
Timothy LaVaute
Miriam Leenders
Nina Lichtenberg
Genevieve Lind
Liza Litvina
Cara Long
Codrin Lungu
Quynh Ly
Timothy Lyden
Ernie Lyons
Laura Mamounas
Marguerite Matthews
Linda McGavern
Barbara McMakin
Carolina Mendoza-Puccini
Bruce Mertz
Mirela Milescu
Daniel Miller
DP Mohapatra
Karen Molina
Marilyn Moore-Hoon
Jill Morris
Claudia Moy
Paul Myers
John Ngai
Glen Nuckolls
Ada O’Donnell
John Ogawa
Ana Olariu
Mara Olenick
Lola Olufemi
Oreisa O’Neil-Mathurin
Michael Oshinsky
David Owens
Mary Ann Pelleymounter
Marlene Peters-Lawrence
Erna Petrich
Leah Pogorzala
Linda Porter
Nia Pree
Rebecca Price
Dvonte Putney
Shamsi Raeissi
Shanta Rajaram
Khara Ramos
Ranga Rangarajan
K. Paul Rezaizadeh
Robert Riddle
Becky Roof
Cheryse Sankar
Joel Saydoff
Rachael Schacherer
Alisa Schaefer
Nina Schor
Paul Scott
Hawa Eve Sesay
Beth-Anne Sieber
Shai Silberberg
Venkat Shanmugan
Smita Sharma
Mario Skiadopoulos
Shardell Spriggs
Kalynda Stokes
Natalia Strunnikova
Sherri Styles
Christine Swanson-Fischer
Edmund Talley
Amir Tamiz
Anna Taylor
Carol Taylor-Burds
Christine Torborg
Delany Torres
Natalie Trzcinski
Alexander Tuttle
Lauren Ullrich
Ursula Utz
Andrea Varea
Oleksandr Vedmid
Joanna Vivalda
Laura Wandner
Jackie Ward
Margo Warren
James Washington
Matt White
Samantha White
Vicky Whittemore
Blessing Williams
Sarah Woller
Ling Wong
May Wong
Clinton Wright
Nick Wymbs
Ye Yan
Bob Zalutsky
Ran Zhang

Other federal employees present for portions of the meeting included:

Dr. Jasenka Borzan, CSR
Dr. Sam Edwards, CSR
Dr. Lisa Gilotty, NIMH
Dr. Peter Guthrie, CSR
Dr. Carole Jelsema, CSR
Dr. Aleksey Kazantsev, CSR
Dr. Holly Moore, NIDA
Dr. Suzan Nadi, CSR
Dr. Elyse Schauwecker, CSR
Ali Shaker, CIT
Dr. Laurent Taupenot, CSR

We certify that, to the best of our knowledge, the foregoing minutes and attachments are accurate and complete.

 

______
Date

_____________________________
Robert Finkelstein, Ph.D.
Executive Secretary
National Advisory Neurological Disorders
and Stroke Council

Director, Division of Extramural Research
National Institute of Neurological Disorders
and Stroke

______
Date
_____________________________
Walter Koroshetz, M.D.
Chairperson
National Advisory Neurological Disorders
and Stroke Council

Director
National Institute of Neurological Disorders
and Stroke

These minutes will be formally considered by the Council at its next meeting. Corrections or notations will be incorporated in the minutes of that meeting

---

¹For the record, it is noted that members absent themselves from the meeting when the Council is discussing applications (a) from their respective institutions or (b) in which a real or apparent conflict of interest might occur.